Prevention & lipidsCohort study
Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls
- Matched cohort study
- age- and sex-matched controls
- registry-based
Costs from Norwegian Patient Registry, Cause of Death Registry and Norwegian Prescription Database; Diagnosis-related group (DRG) cost weights and drug prices (Norwegian kroner 1 = euros (EUR) 0.1015)
Authors' conclusion
Familial hypercholesterolaemia patients had about three times higher CVD-related hospital costs and more than 10 times higher pharmaceutical costs than age- and sex-matched controls during a 10-year follow-up. During the 10 years, costs for pharmaceuticals increased and costs for hospital decreased.
Study context
- Population
- Individuals with genetically verified familial hypercholesterolaemia (FH) (Norwegian Unit for Cardiac and Cardiovascular Genetics registry) and matched controls, Norway, 2010–2019
- Participants
- 5,585 vs 111,483
- Exposure
- Genetically verified FH vs age- and sex-matched controls
- FHn = 5,585
- Controlsn = 111,483reference
- Outcome
- CVD-related hospital and pharmaceutical resource use and costs
- Follow-up
- 2010 through 2019
Main finding
As reported in the abstract
| Group | Hospital care | Pharmaceuticals |
|---|---|---|
| FH | €3911 | €6119 |
| Controls | €1498 | €514 |
Observational data: associations, not effects.
Further findings
| Outcome | FH | Controls |
|---|---|---|
| 10-year PCI costs per person | €561 | €140 |
Trend in cardiovascular disease (CVD) prescription drug costs, 2010-19
- Increase in FH
- P = 0.002
- Increase in controls
- P = 0.005
- Costs doubled in FH, largely due to introduction of PCSK9 inhibitors
Trend in hospital care costs, 2010-19
- Decrease in FH
- P = 0. 0069
- Decrease in controls
- P = 0. 0943
Original publication
Summarised from the published abstract; every number is checked against it